Loading...
•
Mar 31, 2022
Janux Q1 2022 Earnings Report
Janux reported first quarter results with progress in advancing TRACTr and TRACIr programs and a strong cash position.
Key Takeaways
Janux Therapeutics reported a net loss of $13.4 million for the first quarter of 2022. The company's cash and cash equivalents and short-term investments totaled $361.2 million as of March 31, 2022. Janux continues to advance its pipeline of immunotherapies, with IND applications planned for JANX007 and JANX008 in 2022 and TROP2-TRACTr and PD-L1xCD28 TRACIr programs in 2023.
IND application submitted for PSMA-TRACTr (JANX007).
Company remains on-track to submit IND application for EGFR-TRACTr (JANX008) in 2H 2022.
Merck nominated a second target as part of strategic collaboration and license agreement.
Presented preclinical data for JANX007 and JANX008 at the 18th Annual Protein & Antibody Engineering Summit (PEGS) Boston Conference & Expo.
Revenue by Segment
Forward Guidance
Janux is focused on advancing its TRACTr and TRACIr programs, with multiple IND submissions planned in the near future. The company is also continuing to develop its broader pipeline of next-generation immunotherapies.
Positive Outlook
- Advancing TRACTr candidates as planned
- IND application submitted for PSMA-TRACTr (JANX007)
- On track to submit IND application for EGFR-TRACTr (JANX008) in the second half of 2022
- Planning to submit IND application for TROP2-TRACTr in 2023
- IND-enabling studies ongoing for PD-L1xCD28 TRACIr
Challenges Ahead
- Uncertainties associated with performing clinical trials
- Risks associated with reliance on third parties to successfully conduct clinical trials
- Risks associated with reliance on outside financing to meet capital requirements
- The risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...